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1 These authors contributed equally to this work.The small G-protein Rheb regulates cell growth via the mTORC1 complex by incompletely under-
stood mechanisms. Recent studies document that Rheb activates mTORC1 via direct, GTP-dependent
interaction with the peptidyl-prolyl-cis/trans-isomerase FKBP38, which is proposed to act as an
inhibitor of mTORC1. We have conducted a comprehensive biochemical characterization of the
Rheb/FKBP38 interaction. Using three different in vitro assays we did not detect an interaction
between Rheb and FKBP38. Cell biological experiments illustrate that FKBP38 plays only a very
minor, if any, role in mTORC1 activation. Our data document that FKBP38 is not the long-sought
Rheb effector linking Rheb to mTORC1 activation.
Structured summary:
MINT-6946532: Ral (uniprotkb:P11233) binds (MI:0407) to Ha-Ras (uniprotkb:P01112) by pull down
(MI:0096)
MINT-6946500: RAF (uniprotkb:P04049) binds (MI:0407) to RHEB2 (uniprotkb:Q15382) by pull down
(MI:0096)
MINT-6946517: RAF (uniprotkb:P04049) binds (MI:0407) to Ha-Ras (uniprotkb:P01112) by pull down
(MI:0096)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction activity is controlled by environmental and cell-endogenous cuesProtein translation is a tightly regulated process and a major
determinant of cell fate. Both global and selective protein transla-
tion are under the control of the so-denominated mTOR (mamma-
lian target of rapamycin) pathway [1]. The Ser/Thr kinase mTOR
affects protein translation by regulating the activity of the ribo-
somal S6 protein kinase (p70 S6 kinase) and the translation initia-
tion factor binding protein 4E-BP1 [1,2]. Phosphorylation events on
either target protein rev up protein translation, leading to en-
hanced cell growth (i.e., the accumulation of cell mass) and foster-
ing cell proliferation. Accordingly, the mTOR pathway is often
aberrantly activated in human neoplasia [3,4], highlighting its crit-
ical function in the control of cell proliferation.
mTOR is present in two multiprotein complexes only one of
which, mTORC1, is sensitive to the macrolide rapamycin and
responsible for the modulation of protein translation. mTORC1chemical Societies. Published by E
tein; PPIase, peptidyl-prolyl-
Rubio).including metabolic hormones, nutrients and the energy status of
the cell [1]. Investigation of the pathways that funnel these signals
to mTORC1 has recently lead to the identiﬁcation of Rheb, a mem-
ber of the Ras family of small G-proteins, as an upstream regulator
of mTORC1 [1,5]. Insulin and perhaps amino acid sufﬁciency pro-
mote GTP-loading of Rheb via the inhibition of TSC1/TSC2, a tu-
mour suppressor protein complex that acts as a GAP, that is, an
inhibitor of Rheb [5–7]. Elevated levels of active Rheb are sufﬁcient
to activate mTORC1 [5,8]. Rheb is necessary for mTORC1 activation
by Insulin and amino acids [6] and Rheb overexpression restores
mTORC1 activity in cells deprived of amino acids [9]. While such
data demonstrate that Rheb regulates mTORC1, a number of ﬁnd-
ings have made clear that mTOR itself is not an effector of Rheb.
mTOR copuriﬁes with Rheb from cell lysates, but the interaction
is independent of the nucleotide loading status of Rheb because
RhebS20N, a mutant most likely to exist in the nucleotide-free
state, exhibits a strong association with mTOR [9]. Similarly,
RhebT38M, a mutant rendered inactive through a mutation in its
effector binding region, co-precipitates with mTORC1 [9]. These
observations indicate that mTOR is not a direct target of Rheb
and point to the existence of yet unknown Rheb-effector(s).lsevier B.V. All rights reserved.
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binding protein (FKBP) family are predicted to assist in protein
folding processes in a chaperone-like fashion. One member,
FKBP38, possesses features that render this protein unique within
this class of enzymes: For example, the PPIase activity of FKBP38 is
strictly dependent on Ca2+/calmodulin and, unlike all other FKBPs,
FKBP38 possesses a transmembrane domain that targets it to endo-
membranes [10]. Pharmacological inhibitors of FKBP38 have
strong neuroprotective and regenerative properties [11], arguing
for a role of FKBP38’s PPIase activity in the regulation of cell sur-
vival/viability. However, the underlying mechanism and the iden-
tity of interaction partners and/or substrates for FKBP38 are largely
unknown.
Recent studies from the Jiang laboratory have provided evi-
dence for a role of FKBP38 as a regulator of mTORC1. FKBP38 is re-
ported to interact with and thereby inhibit mTORC1 activity
[12,13]. According to the same model, mTORC1 is released from
inhibition by active Rheb, which binds to FKBP38 in a GTP-depen-
dent fashion, thereby displacing FKBP38 from mTORC1. We have
investigated in detail the interaction between Rheb and FKBP38
to examine if FKBP38 fulﬁls the criteria of a bona ﬁde effector pro-
tein of Rheb. Results obtained with three different protein interac-
tion assays document that Rheb and FKBP38 do not physically
interact, questioning the proposed role of FKBP38 as a Rheb effec-
tor in the mTORC1 pathway.2. Materials and methods
2.1. Materials
4 x siRNA set against human FKBP38 (ON-TARGETplus SMART-
pool) and control siRNA were purchased from Dharmacon (Lafay-
ette, USA). Transfection reagent SAINT-RED for siRNA delivery
was from Synvolux Therapeutics (Groningen, Netherlands). Insulin
from bovine pancreas and polyethyleneimine were from Sigma–
Aldrich (Taufkirchen, Germany). Rapamycine was from Calbio-
chem (Schwalbach, Germany). DM-CHX was synthesized as
described in Edlich et al. [11]. The following antibodies were em-
ployed: phospho-p70 S6 Kinase (T421/Ser424) (cat# 9204), phos-
pho-p70 S6 Kinase (T389) (cat# 9205), p70 S6 Kinase (cat#
9202), phospho-S6 protein(Ser235/Ser236) (cat# 2211), S6 protein
(cat# 2217), 4E-BP1 (cat# 9452), phospho-4E-BP1 (T70) (cat#
9455) were purchased from Cell Signalling (Danvers, USA). Anti
Rheb (cat# sc-6341) was from Santa Cruz (Heidelberg, Germany).
Polyclonal sera against FKBP38, FKBP51 and FKBP52 are described
elsewhere [14].
2.2. Expression plasmids
Bacterial expression plasmids for His-Ha-Ras, GST-Raf-RBD and
GST-RalGDS-RBD have been described before [15]. hsRheb (1–184)
was cloned Bg/II/EcoRI in BamHI/EcoRI in pGEX-2T and Xho/EcoRI
in pRSET-A. hsRheb (1–170) was cloned BamHI/XhoI in pGEX 4T-
1. HA-Rheb (hs) in pcDNA4/TO was a kind gift of Fried Zwartkruis,
Utrecht, Netherlands. hsFKBP38 (long variant, locus AAO39020)
(1–386) in pGEX 6P-1 was provided by Yu Jiang, Pittsburgh, USA.
Expression plasmids for hsFKBP38 (short variant, locus Q14318)
(58–370) and the PPIAse domain of FKBP38 (35–153) have been
described before [16]. The integrity of all constructs was veriﬁed
by sequencing.
2.3. Protein puriﬁcation
Recombinant human FKBP38 and full length or C-terminally
truncated Rheb were expressed as GST fusion proteins inEscherichia coli BL21(DE3) cells. Expression was induced at an
OD600 of 0.6 with 0.1 mM IPTG and cells were incubated overnight
(Rheb) or 4 h (FKBP38) at 20 C. Cell lysate supernatants were ap-
plied to a GSH column. In the case of Rheb the GST-tag was re-
moved by cleavage. Eluted proteins were further puriﬁed by size
exclusion chromatography using Superdex S75 26/60 (Rheb) or
S200 16/60 (FKBP38) columns preequilibrated with a buffer con-
taining 50 mM Tris–HCl, pH 7.5, 5 mM MgCl2 and 3 mM DTE, sup-
plemented with 50 mM (Rheb) or 150 mM NaCl (FKBP38). Full
length Rheb expressed as His-fusion protein in E. coli BL21(DE3)
plys cells was puriﬁed as described for Ras in Ref. [15]. Full loading
of Rheb with different nucleotides was carried out essentially as
described [17] and monitored by HPLC. The PPIAse domain of
FKBP38 was expressed as described [16].
2.4. GST pulldown assays
GST-FKBP38, GST or GST-RBD fusion proteins (at 0.2 lM) were
incubated for 30 min at 4 C with an equal concentration of Rheb
or Ha-Ras as isolated from bacteria (untreated, GDP/GTP loaded)
or fully loaded with GDP, GppNHp or GTP in a ﬁnal volume of
500 lL assay buffer (30 mM Tris, pH 7.5, 100 mM NaCl, 5 mM
MgCl2, 3 mM DTE, and 0.1% Triton X-100). GST fused proteins were
captured on 30 lL of preequilibrated GSH sepharose beads for
30 min at 4 C followed by 4 wash steps with an excess of assay
buffer and SDS–PAGE/Western blot analysis. Reciprocal pulldown
assays using GST-Rheb and free FKBP38 (aa 35–153) were modiﬁed
accordingly.
2.5. Fluorescence measurements
Measurements were performed at 25 C in a buffer containing
30 mM Tris–HCl, pH 7.5, 100 mM NaCl, 10 mM Na2HPO4/NaH2PO4,
pH 7.5, and 3 mM DTE, supplemented with 2 mM (GDI assay) or
5 mM MgCl2 (ﬂuorescence polarization assay). Data were recorded
with a FluoroMax-4 spectroﬂuorometer (Horiba Jobin Yvon,
Edison, NJ, USA), with excitation and emission wavelengths of
mant-nucleotides at 366 nm and 450 nm, respectively. Nucleotide
dissociation of mGppNHp from 1 lM Rheb (1–184) was started by
adding 100 lM of unlabeled nucleotide in the absence or presence
of 10 lM GST-FKBP38 (1–386). Fluorescence polarization upon
addition of 20 lM GST-FKBP38 (1–386) in two aliquots to 3 lM
mGppNHp-bound Rheb (1–184) was integrated over at least
30 min, corresponding to at least 60 measured values.
2.6. Cell culture
Early passage HEK293 cells were cultured in DMEM medium
supplemented with 10% FCS in a 5% CO2 atmosphere and subcul-
tured by mechanic dislodgement. 16–20 h prior to all experiments
cells were deprived of serum.
2.7. siRNA and plasmid transfection
All siRNAs were dissolved at a ﬁnal, total concentration of
20 lM in RNAse free water,aliquoted and stored at 20 C. Trans-
fection into HEK293 cells was accomplished with SAINT-RED re-
agent according to the manufacturer’s instructions. HA-tagged
Rheb in pcDNA4/TO was transfected into HEK293 by a polyethy-
lenimine based procedure exactly as described [18].
2.8. Cell stimulation, cell lysis and analysis of S6K phosphorylation
HEK-293 cells were stimulated with 5 lg/ml Insulin for varying
periods of time and lysed in 1 ml ice-cold lysis solution (50 mM
HEPES pH 7.5, 140 mM NaCl, 5 mM EDTA, 1 mM EGTA, 1% NP40,
GS
T-
FK
BP
38
(1
-3
86
)
Rh
eb
(1
-1
84
)
Rh
eb
(1
-1
70
)
66
36
20
A
24
Coomassie
GDP
Untreated
GppNHp
-+
+
+
- - -
--
+--
-+
+
+
- - -
--
+--
Rh
eb
(1
-1
84
)
Rh
eb
(1
-1
70
)
Rh
eb
(1
-1
84
)
Rh
eb
(1
-1
70
)
-+
+
+
- - -
--
+--
-+
+
+
- - -
--
+--
Rh
eb
(1
-1
84
)
Rh
eb
(1
-1
70
)
Rh
eb
(1
-1
84
)
Rh
eb
(1
-1
70
)
IB: GST-tag
IB: Rheb
GST GST-FKBP38 GST-FKBP38GST
Input Pulldown
B
66
36
24
20
C
FK
BP
38
Ra
f-R
BD
Ra
lG
DS
RB
D
FK
BP
38
Ra
f-R
BD
Ra
lG
DS
RB
D
GDP
GppNHp
+ - + - + - + - + - + -
+-+-+-+-+-+-
His-Rheb His-Ha-Ras
62
47
32
83
175
25
32
25
Pulldown
Coomassie
Pulldown
IB: His-tag
Load
IB: His-tag
Coomassie
IB: FKBP38
GDP
GppNHp
+ - + -
+-+-
+ - + -
+-+-
GST-
Rheb
GST-
Rheb
GST-
Ras
GST-
Ras
62
32
25
16
BSA
GST-Rheb/Ras
FKBP38-PPIase
Pulldown Load
D
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and a mix of protease inhibitors). Lysates were cleared by
centrifugation, resolved by SDS–PAGE and processed by Western
blotting.
3. Results and discussion
Recent studies have put forward a molecular framework of
mTORC1 regulation by Rheb that implies a role for FKBP38 as an
effector of Rheb [12,13]. In order to characterize the Rheb/FKBP38
interaction we expressed and puriﬁed Rheb and FKBP38 to high
purity (Fig. 1A). All FKBP38 fragments employed were correctly
folded, as judged by Bcl2 binding and by the presence of in vitro
PPIase activity [10,16]. Full-length or C-terminally truncated, un-
tagged Rheb was loaded with different nucleotides and loadingefﬁciency was veriﬁed by HPLC analysis [19]. Rheb proteins were
incubated with a GST-FKBP38 fusion protein expressing the cyto-
solic portion of human FKBP38 and subjected to a GST pulldown
assay. As shown in Fig. 1B no interaction between Rheb and
FKBP38 was observed. Experiments using His-tagged Rheb (the
variant reported to interact with FKBP38 [12]) produced the same
negative result (Fig. 1C). To ascertain the functionality of the assay,
we run parallel reactions with Ras-GDP/GTP and the established
Ras effectors Raf-RBD and RalGDS-RBD (Fig. 1C). Ras interacted
with both RBDs in a GTP-dependent manner, showing that the as-
say conditions were suited to detect G-protein/effector interac-
tions. Noteworthy, this experiment evidenced an interaction of
Rheb-GDP and Rheb-GTP with Raf-RBD, conﬁrming ﬁndings that
illustrate the fundamental ability of Rheb to interact with the
RBD of c-Raf [20].
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GST-FKBP38 immobilisation, we run the reciprocal experiment.
GST-tagged full-length Rheb pre-loaded with nucleotides was used
to pulldown the isolated, untagged PPIase domain of FKBP38 (the
proposed interaction site for Rheb on FKBP38 [13]). This experi-
ment also showed no interaction between both polypeptides
(Fig. 1D). Several variants of FKBP38, arising from alternative splic-
ing and other processes, have been described [21]. We tested both
the longest described FKBP38 variant (locus AAO39020) and a var-
iant lacking the ﬁrst N-terminal 57 amino acids (locus Q14318)
and observed no interaction with Rheb-GTP with either protein.
Of note, variant AAO39020 is the polypeptide previously reported
to interact with Rheb [12].
Since these ﬁndings were in conﬂict to the reported Rheb/
FKBP38 interaction, we performed solution binding studies to
avoid the use of any solid phase because this is a major cause of
artefacts in protein-protein interaction studies. Binding to effectors
inhibits the dissociation of nucleotides from Ras-like G-proteins
[17]. This so called guanine nucleotide dissociation inhibition
(GDI) assay showed no effect of FKBP38 on the dissociation of ﬂuo-
rescent mGppNHp (a non-hydrolyzable GTP analogue) from Rheb
(Fig. 2A). Also, ﬂuorescence polarization of the mGppNHp-Rheb
complex (another G-protein feature known to be sensitive to effec-
tor binding) was not affected by FKBP38, using either of the
FKBP38 variants described above (Fig. 2B and data not shown). In
sum, solution binding assays corroborated that Rheb does not
interact with FKBP38.
Although the reasons for the discrepancy between our data and
those of Jiang and co-workers are not immediately obvious, we
note that the authors did not monitor the efﬁciency of nucleotide
loading on Rheb. Also, Jiang and co-workers used magnesium-free
solutions for their in vitro interaction analysis, and the lysis solu-
tion used for the Rheb/FKBP38 co-immunoprecipitation analysis62.5
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tide binding site. Under these conditions Rheb and other small G-
proteins are unable to form stable complexes with guanine nucle-
otides. We suspect that the different reaction conditions are a
likely cause for the observed discrepancies.
Since the present data negated a role of FKBP38 as an effector of
Rheb in mTORC1 activation, we investigated mTORC1 regulation in
HEK293 cells. siRNA based knockdown of FKBP38 caused a higher
degree of insulin dependent S6K phosphorylation on T389, a bona
ﬁde phosphorylation site of mTOR [22] (Fig. 3A, quantiﬁed in
Fig. 3B). This observation agrees with data by Bai et al. that identify
FKBP38 as a negative regulator of mTORC1 signalling [12]. How-
ever, the effect of FKBP38 ablation on Insulin driven T389 phos-
phorylation was very mild (see quantiﬁcation in Fig. 3B). Also,
despite an almost complete FKBP38 knockdown, we detected no
changes at various other levels including a second phosphorylation
motif on S6K (T421/S424), phosphorylation of ribosomal S6 protein
on S235/S236 or T70 phosphorylation on 4E-BP1. Since Insulin in-
duced phosphorylation of all these motifs depends on Rheb
[5,6,8,9], these ﬁndings argued against a role of FKBP38 in Rheb-
dependent mTORC1 activation.
To exclude the formal possibility that Rheb-independent path-
ways became operative in a background of reduced FKBP38 levels,
we investigated the consequences of FKBP38 knockdown on
mTORC1 activation driven by overexpressed Rheb. We reasoned
that if Rheb activated mTORC1 by displacing bound FKBP38, a pro-
nounced reduction in FKBP38 levels should render mTORC1 com-
plexes unresponsive to Rheb. As shown in Fig. 3C rapamycin
sensitive (and therefore mTORC1 mediated) S6K-T389 phosphory-
lation induced by overexpressed Rheb was not signiﬁcantly altered
in the virtually complete absence of FKBP38 (knockdown efﬁ-
ciency: >95%). Taken together with the lack of binding between
Rheb and FKBP38, and with the mild consequences of FKBP38IB: S6K
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970 K. Uhlenbrock et al. / FEBS Letters 583 (2009) 965–970knockdown on Insulin induced mTORC1 activation, the most
straightforward interpretation is that Rheb does not necessitate
FKBP38 to activate mTORC1. This conclusion is largely in line with
recent data by Wang et al. who were unable to detect an effect of
FKBP38 on mTORC1 activity or a nucleotide-dependent co-immu-
noprecipitation of Rheb and FKBP38 [23].
Since our ﬁndings argued against a role of FKBP38 as a mediator
of Rheb’s effects on mTORC1, we wondered how FKBP38 exerted
inhibition of p70-S6K-T389 phosphorylation in Insulin stimulated
cells (see Fig. 3A and B). To address if the PPIase activity of FKBP38
played a role in the process, we used DM-CHX, a speciﬁc inhibitor
of FKBP38 [11]. DM-CHX administration enhanced insulin depen-
dent S6K phosphorylation on T389 but not on T421/S424
(Fig. 4A, quantiﬁcation in Fig. 4B). S235/S236 phosphorylation on
ribosomal S6 protein was also unaltered. These effects were spe-
ciﬁc, because DM-CHX did not elevate p70-S6K T389 phosphoryla-
tion in cells devoid of FKBP38 (Fig. 4C). It appeared striking to us
that the effect of DM-CHX was essentially undistinguishable from
the consequences of FKBP38 protein knockdown shown in
Fig. 3A, which provided strong evidence for a role of the PPIase
activity of FKBP38 in the control of S6K T389 phosphorylation.
In conclusion, our data disagree with the competition model of
Rheb-dependent mTOR regulation [12,13]. We document that
FKBP38 is not an effector of Rheb and propose, as do others [23],
that Rheb regulates mTORC1 via a still unknown effector(s).
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